Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

COMPLETED NA

The Visual Effect of an Investigational Artificial Tear in the Tear Layer.

NCT00395759 · View on ClinicalTrials.gov ↗

Study Summary

The purpose of this study is to investigate how the addition of a new artificial tear product when applied to the tear layer affects contrast sensitivity and optical aberrations over time. We will also determine if there are any adverse effects associated with drop instillation.

Conditions Studied

Interventions

  • DRUG Optiva artificial tear by Allergan

Study Locations (1)

California

  • Southern California College of Optometry — Fullerton

Trial Details

FieldValue
Enrollment Target 30 participants
Start Date 2005-09
Est. Completion 2007-09
Phase NA

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00395759

The ClinicalTrials.gov registry entry for NCT00395759 describes a study currently listed as completed. It is categorized as NA, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Southern California College of Optometry at Marshall B. Ketchum University, which has 4 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 1 condition, with Dry Eye Disease appearing as the primary indexed condition, and to 1 intervention — of which Optiva artificial tear by Allergan is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT00395759 reports 1 study location spanning 1 distinct geographic area — top geographies include California. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT00395759 about?

NCT00395759 is a clinical study titled "The Visual Effect of an Investigational Artificial Tear in the Tear Layer.". The purpose of this study is to investigate how the addition of a new artificial tear product when applied to the tear layer affects contrast sensitivity and optical aberrations over time. We will also determine if there are any adverse effects associated with drop instillation.

What is the current status of trial NCT00395759?

This trial is currently completed. It is a NA study. The enrollment target is 30 participants. The study started on 2005-09. Estimated completion is 2007-09.

What conditions does trial NCT00395759 study?

This clinical trial studies the following conditions: Dry Eye Disease. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

What interventions are being tested in trial NCT00395759?

The interventions under investigation include: Optiva artificial tear by Allergan (DRUG). Each intervention is being evaluated for safety and efficacy as part of this clinical study.

Who is sponsoring clinical trial NCT00395759?

This trial is sponsored by Southern California College of Optometry at Marshall B. Ketchum University, which has 4 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT00395759 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial